465 related articles for article (PubMed ID: 16024626)
1. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
Capurro MI; Xiang YY; Lobe C; Filmus J
Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
Capurro M; Martin T; Shi W; Filmus J
J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
Filmus J; Capurro M
FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
[TBL] [Abstract][Full Text] [Related]
4. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells.
Qin X; Zhang H; Zhou X; Wang C; Zhang H; Zhang X; Ye L
Transl Res; 2007 Nov; 150(5):281-94. PubMed ID: 17964517
[TBL] [Abstract][Full Text] [Related]
5. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma.
Hu J; Dong A; Fernandez-Ruiz V; Shan J; Kawa M; MartÃnez-Ansó E; Prieto J; Qian C
Cancer Res; 2009 Sep; 69(17):6951-9. PubMed ID: 19690140
[TBL] [Abstract][Full Text] [Related]
6. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
Zittermann SI; Capurro MI; Shi W; Filmus J
Int J Cancer; 2010 Mar; 126(6):1291-301. PubMed ID: 19816934
[TBL] [Abstract][Full Text] [Related]
7. Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth.
Capurro MI; Shi W; Sandal S; Filmus J
J Biol Chem; 2005 Dec; 280(50):41201-6. PubMed ID: 16227623
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
Kandil DH; Cooper K
Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
[TBL] [Abstract][Full Text] [Related]
10. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression.
Fukutomi T; Zhou Y; Kawai S; Eguchi H; Wands JR; Li J
Hepatology; 2005 May; 41(5):1096-105. PubMed ID: 15841445
[TBL] [Abstract][Full Text] [Related]
12. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
Li N; Wei L; Liu X; Bai H; Ye Y; Li D; Li N; Baxa U; Wang Q; Lv L; Chen Y; Feng M; Lee B; Gao W; Ho M
Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
15. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 expression is silenced in human breast cancer.
Xiang YY; Ladeda V; Filmus J
Oncogene; 2001 Nov; 20(50):7408-12. PubMed ID: 11704870
[TBL] [Abstract][Full Text] [Related]
17. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
19. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]